SCHEDULE 13G: BlackRock Discloses 5.0% Passive Stake in Elanco Animal Health Inc
Beneficial Ownership Disclosure
BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.0% of Elanco Animal Health Inc's common stock as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 24,865,467 shares of Elanco Animal Health Inc's common stock.
- This represents 5.0% of the total outstanding common stock of Elanco Animal Health Inc.
- The filing is a Schedule 13G, indicating that BlackRock holds these shares for passive investment purposes and not with the intent to change or influence control of the issuer.
- The beneficial ownership includes sole voting power over 22,981,479 shares and sole dispositive power over 24,865,467 shares.
- The filing date was February 4, 2025, with the ownership position reported as of December 31, 2024.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership by a large institutional investor, BlackRock, Inc., in Elanco Animal Health Inc. It does not contain performance metrics or forward-looking statements that would indicate a positive or negative sentiment regarding the issuer's operations. The passive nature of the investment (13G filing) suggests a standard portfolio holding.
Positives
- The disclosure of a 5.0% stake by a major institutional investor like BlackRock can signal confidence in Elanco Animal Health Inc's long-term prospects.
- The filing under Rule 13d-1(b) indicates a passive investment intent, suggesting BlackRock is not seeking to exert control or influence management, which can be viewed positively by current management and other passive investors.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The disclosure of a significant passive stake by BlackRock may enhance investor confidence and potentially contribute to stock stability due to a large, long-term holder.
- Management: The passive nature of the investment (Rule 13d-1(b)) indicates that BlackRock is not seeking to influence or challenge Elanco's management or corporate control.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date for beneficial ownership) |
| 01/21/2025 | Date of Power of Attorney execution |
| 02/04/2025 | Date of Schedule 13G filing |
Keywords
Elanco Animal Health Inc, BlackRock, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, animal health
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.